<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">31744522</PMID><DateCompleted><Year>2020</Year><Month>06</Month><Day>23</Day></DateCompleted><DateRevised><Year>2020</Year><Month>06</Month><Day>23</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1750-1326</ISSN><JournalIssue CitedMedium="Internet"><Volume>14</Volume><Issue>1</Issue><PubDate><Year>2019</Year><Month>Nov</Month><Day>19</Day></PubDate></JournalIssue><Title>Molecular neurodegeneration</Title><ISOAbbreviation>Mol Neurodegener</ISOAbbreviation></Journal><ArticleTitle>Wild-type Cu/Zn-superoxide dismutase is misfolded in cerebrospinal fluid of sporadic amyotrophic lateral sclerosis.</ArticleTitle><Pagination><StartPage>42</StartPage><MedlinePgn>42</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">42</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s13024-019-0341-5</ELocationID><Abstract><AbstractText Label="BACKGROUND">A subset of familial forms of amyotrophic lateral sclerosis (ALS) are caused by mutations in the gene coding Cu/Zn-superoxide dismutase (SOD1). Mutant SOD1 proteins are susceptible to misfolding and abnormally accumulated in spinal cord, which is most severely affected in ALS. It, however, remains quite controversial whether misfolding of wild-type SOD1 is involved in more prevalent sporadic ALS (sALS) cases without SOD1 mutations.</AbstractText><AbstractText Label="METHODS">Cerebrospinal fluid (CSF) from patients including sALS as well as several other neurodegenerative diseases and non-neurodegenerative diseases was examined with an immunoprecipitation assay and a sandwich ELISA using antibodies specifically recognizing misfolded SOD1.</AbstractText><AbstractText Label="RESULTS">We found that wild-type SOD1 was misfolded in CSF from all sALS cases examined in this study. The misfolded SOD1 was also detected in CSF from a subset of Parkinson's disease and progressive supranuclear palsy, albeit with smaller amounts than those in sALS. Furthermore, the CSF samples containing the misfolded SOD1 exhibited significant toxicity toward motor neuron-like NSC-34 cells, which was ameliorated by removal of the misfolded wild-type SOD1 with immunoprecipitation.</AbstractText><AbstractText Label="CONCLUSIONS">Taken together, we propose that misfolding of wild-type SOD1 in CSF is a common pathological process of ALS cases regardless of SOD1 mutations.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Tokuda</LastName><ForeName>Eiichi</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Laboratory for Mechanistic Chemistry of Biomolecules, Department of Chemistry, Keio University, Yokohama, 223-8522, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Takei</LastName><ForeName>Yo-Ichi</ForeName><Initials>YI</Initials><AffiliationInfo><Affiliation>Department of Neurology, Matsumoto Medical Center, Matsumoto, 399-0021, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ohara</LastName><ForeName>Shinji</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Neurology, Matsumoto Medical Center, Matsumoto, 399-0021, Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Iida Hospital, Iida, 395-8505, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fujiwara</LastName><ForeName>Noriko</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Biochemistry, Hyogo College of Medicine, Nishinomiya, 663-8501, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hozumi</LastName><ForeName>Isao</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Laboratory of Medical Therapeutics and Molecular Therapeutics, Gifu Pharmaceutical University, Gifu, 501-1196, Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology and Geriatrics, Gifu University Graduate School of Medicine, Gifu, 501-1194, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Furukawa</LastName><ForeName>Yoshiaki</ForeName><Initials>Y</Initials><Identifier Source="ORCID">0000-0002-1918-372X</Identifier><AffiliationInfo><Affiliation>Laboratory for Mechanistic Chemistry of Biomolecules, Department of Chemistry, Keio University, Yokohama, 223-8522, Japan. furukawa@chem.keio.ac.jp.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2019</Year><Month>11</Month><Day>19</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Mol Neurodegener</MedlineTA><NlmUniqueID>101266600</NlmUniqueID><ISSNLinking>1750-1326</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000606290">SOD1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.15.1.1</RegistryNumber><NameOfSubstance UI="D000072105">Superoxide Dismutase-1</NameOfSubstance></Chemical><Chemical><RegistryNumber>J41CSQ7QDS</RegistryNumber><NameOfSubstance UI="D015032">Zinc</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName><QualifierName UI="Q000201" MajorTopicYN="Y">enzymology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009046" MajorTopicYN="N">Motor Neurons</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017510" MajorTopicYN="N">Protein Folding</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013116" MajorTopicYN="N">Spinal Cord</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000072105" MajorTopicYN="N">Superoxide Dismutase-1</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015032" MajorTopicYN="N">Zinc</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Amyotrophic lateral sclerosis (ALS)</Keyword><Keyword MajorTopicYN="N">Cerebrospinal fluid (CSF)</Keyword><Keyword MajorTopicYN="N">Cu/Zn-superoxide dismutase (SOD1)</Keyword><Keyword MajorTopicYN="N">Protein misfolding</Keyword></KeywordList><CoiStatement>The authors declare that they have no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>5</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2019</Year><Month>10</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>11</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>11</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>6</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31744522</ArticleId><ArticleId IdType="pmc">PMC6862823</ArticleId><ArticleId IdType="doi">10.1186/s13024-019-0341-5</ArticleId><ArticleId IdType="pii">10.1186/s13024-019-0341-5</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Andersen PM, Al-Chalabi A. Clinical genetics of amyotrophic lateral sclerosis: what do we really know? Nat Rev Neurol. 2011;7:603&#x2013;615. doi: 10.1038/nrneurol.2011.150.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrneurol.2011.150</ArticleId><ArticleId IdType="pubmed">21989245</ArticleId></ArticleIdList></Reference><Reference><Citation>Robberecht W, Philips T. The changing scene of amyotrophic lateral sclerosis. Nat Rev Neurosci. 2013;14:248&#x2013;264. doi: 10.1038/nrn3430.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrn3430</ArticleId><ArticleId IdType="pubmed">23463272</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosen DR, Siddique T, Patterson D, Figlewicz DA, Sapp P, Hentati A, et al. Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature. 1993;362:59&#x2013;62.</Citation><ArticleIdList><ArticleId IdType="pubmed">8446170</ArticleId></ArticleIdList></Reference><Reference><Citation>Chio A, Traynor BJ, Lombardo F, Fimognari M, Calvo A, Ghiglione P, et al. Prevalence of SOD1 mutations in the Italian ALS population. Neurology. 2008;70:533&#x2013;537. doi: 10.1212/01.wnl.0000299187.90432.3f.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/01.wnl.0000299187.90432.3f</ArticleId><ArticleId IdType="pubmed">18268245</ArticleId></ArticleIdList></Reference><Reference><Citation>Kwon MJ, Baek W, Ki CS, Kim HY, Koh SH, Kim JW, et al. Screening of the SOD1, FUS, TARDBP, ANG, and OPTN mutations in Korean patients with familial and sporadic ALS. Neurobiol Aging. 2012;33:1017 e1017&#x2013;1017 e1023. doi: 10.1016/j.neurobiolaging.2011.12.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2011.12.003</ArticleId><ArticleId IdType="pubmed">22244934</ArticleId></ArticleIdList></Reference><Reference><Citation>Julien JP. Amyotrophic lateral sclerosis. Unfolding the toxicity of the misfolded. Cell. 2001;104:581&#x2013;591. doi: 10.1016/S0092-8674(01)00244-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0092-8674(01)00244-6</ArticleId><ArticleId IdType="pubmed">11239414</ArticleId></ArticleIdList></Reference><Reference><Citation>Anzai Itsuki, Tokuda Eiichi, Mukaiyama Atsushi, Akiyama Shuji, Endo Fumito, Yamanaka Koji, Misawa Hidemi, Furukawa Yoshiaki. A misfolded dimer of Cu/Zn-superoxide dismutase leading to pathological oligomerization in amyotrophic lateral sclerosis. Protein Science. 2017;26(3):484&#x2013;496. doi: 10.1002/pro.3094.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/pro.3094</ArticleId><ArticleId IdType="pmc">PMC5326558</ArticleId><ArticleId IdType="pubmed">27977888</ArticleId></ArticleIdList></Reference><Reference><Citation>Furukawa Y, Kaneko K, Yamanaka K, O'Halloran TV, Nukina N. Complete loss of post-translational modifications triggers fibrillar aggregation of SOD1 in familial form of ALS. J Biol Chem. 2008;283:24167&#x2013;24176. doi: 10.1074/jbc.M802083200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M802083200</ArticleId><ArticleId IdType="pmc">PMC3259764</ArticleId><ArticleId IdType="pubmed">18552350</ArticleId></ArticleIdList></Reference><Reference><Citation>Toichi K, Yamanaka K, Furukawa Y. Disulfide scrambling describes the oligomer formation of superoxide dismutase (SOD1) proteins in the familial form of amyotrophic lateral sclerosis. J Biol Chem. 2013;288:4970&#x2013;4980. doi: 10.1074/jbc.M112.414235.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M112.414235</ArticleId><ArticleId IdType="pmc">PMC3576100</ArticleId><ArticleId IdType="pubmed">23264618</ArticleId></ArticleIdList></Reference><Reference><Citation>Bosco DA, Morfini G, Karabacak NM, Song Y, Gros-Louis F, Pasinelli P, et al. Wild-type and mutant SOD1 share an aberrant conformation and a common pathogenic pathway in ALS. Nat Neurosci. 2010;13:1396&#x2013;1403. doi: 10.1038/nn.2660.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn.2660</ArticleId><ArticleId IdType="pmc">PMC2967729</ArticleId><ArticleId IdType="pubmed">20953194</ArticleId></ArticleIdList></Reference><Reference><Citation>Forsberg Karin, Graffmo Karin, Pakkenberg Bente, Weber Markus, Nielsen Martin, Marklund Stefan, Br&#xe4;nnstr&#xf6;m Thomas, Andersen Peter Munch. Misfolded SOD1 inclusions in patients with mutations in C9orf72 and other ALS/FTD-associated genes. Journal of Neurology, Neurosurgery &amp; Psychiatry. 2019;90(8):861&#x2013;869. doi: 10.1136/jnnp-2018-319386.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2018-319386</ArticleId><ArticleId IdType="pmc">PMC6691870</ArticleId><ArticleId IdType="pubmed">30992335</ArticleId></ArticleIdList></Reference><Reference><Citation>Grad Leslie I., Yerbury Justin J., Turner Bradley J., Guest William C., Pokrishevsky Edward, O&#x2019;Neill Megan A., Yanai Anat, Silverman Judith M., Zeineddine Rafaa, Corcoran Lisa, Kumita Janet R., Luheshi Leila M., Yousefi Masoud, Coleman Bradley M., Hill Andrew F., Plotkin Steven S., Mackenzie Ian R., Cashman Neil R. Intercellular propagated misfolding of wild-type Cu/Zn superoxide dismutase occurs via exosome-dependent and -independent mechanisms. Proceedings of the National Academy of Sciences. 2014;111(9):3620&#x2013;3625. doi: 10.1073/pnas.1312245111.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1312245111</ArticleId><ArticleId IdType="pmc">PMC3948312</ArticleId><ArticleId IdType="pubmed">24550511</ArticleId></ArticleIdList></Reference><Reference><Citation>Pare B, Lehmann M, Beaudin M, Nordstrom U, Saikali S, Julien JP, et al. Misfolded SOD1 pathology in sporadic amyotrophic lateral sclerosis. Sci Rep. 2018;8:14223. doi: 10.1038/s41598-018-31773-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-018-31773-z</ArticleId><ArticleId IdType="pmc">PMC6155098</ArticleId><ArticleId IdType="pubmed">30242181</ArticleId></ArticleIdList></Reference><Reference><Citation>Graffmo K. S., Forsberg K., Bergh J., Birve A., Zetterstrom P., Andersen P. M., Marklund S. L., Brannstrom T. Expression of wild-type human superoxide dismutase-1 in mice causes amyotrophic lateral sclerosis. Human Molecular Genetics. 2012;22(1):51&#x2013;60. doi: 10.1093/hmg/dds399.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/dds399</ArticleId><ArticleId IdType="pubmed">23026746</ArticleId></ArticleIdList></Reference><Reference><Citation>Choi J, Rees HD, Weintraub ST, Levey AI, Chin LS, Li L. Oxidative modifications and aggregation of Cu,Zn-superoxide dismutase associated with Alzheimer and Parkinson diseases. J Biol Chem. 2005;280:11648&#x2013;11655. doi: 10.1074/jbc.M414327200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M414327200</ArticleId><ArticleId IdType="pubmed">15659387</ArticleId></ArticleIdList></Reference><Reference><Citation>Trist BG, Davies KM, Cottam V, Genoud S, Ortega R, Roudeau S, et al. Amyotrophic lateral sclerosis-like superoxide dismutase 1 proteinopathy is associated with neuronal loss in Parkinson's disease brain. Acta Neuropathol. 2017;134:113&#x2013;127. doi: 10.1007/s00401-017-1726-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-017-1726-6</ArticleId><ArticleId IdType="pubmed">28527045</ArticleId></ArticleIdList></Reference><Reference><Citation>Da Cruz S, Bui A, Saberi S, Lee SK, Stauffer J, McAlonis-Downes M, et al. Misfolded SOD1 is not a primary component of sporadic ALS. Acta Neuropathol. 2017;134:97&#x2013;111. doi: 10.1007/s00401-017-1688-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-017-1688-8</ArticleId><ArticleId IdType="pmc">PMC5472502</ArticleId><ArticleId IdType="pubmed">28247063</ArticleId></ArticleIdList></Reference><Reference><Citation>Kerman A, Liu HN, Croul S, Bilbao J, Rogaeva E, Zinman L, et al. Amyotrophic lateral sclerosis is a non-amyloid disease in which extensive misfolding of SOD1 is unique to the familial form. Acta Neuropathol. 2010;119:335&#x2013;344. doi: 10.1007/s00401-010-0646-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-010-0646-5</ArticleId><ArticleId IdType="pubmed">20111867</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu HN, Sanelli T, Horne P, Pioro EP, Strong MJ, Rogaeva E, et al. Lack of evidence of monomer/misfolded superoxide dismutase-1 in sporadic amyotrophic lateral sclerosis. Ann Neurol. 2009;66:75&#x2013;80. doi: 10.1002/ana.21704.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.21704</ArticleId><ArticleId IdType="pubmed">19670443</ArticleId></ArticleIdList></Reference><Reference><Citation>Ayers JI, Xu G, Pletnikova O, Troncoso JC, Hart PJ, Borchelt DR. Conformational specificity of the C4F6 SOD1 antibody; low frequency of reactivity in sporadic ALS cases. Acta Neuropathol Commun. 2014;2:55. doi: 10.1186/2051-5960-2-55.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/2051-5960-2-55</ArticleId><ArticleId IdType="pmc">PMC4035506</ArticleId><ArticleId IdType="pubmed">24887207</ArticleId></ArticleIdList></Reference><Reference><Citation>Haidet-Phillips AM, Hester ME, Miranda CJ, Meyer K, Braun L, Frakes A, et al. Astrocytes from familial and sporadic ALS patients are toxic to motor neurons. Nat Biotechnol. 2011;29:824&#x2013;828. doi: 10.1038/nbt.1957.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nbt.1957</ArticleId><ArticleId IdType="pmc">PMC3170425</ArticleId><ArticleId IdType="pubmed">21832997</ArticleId></ArticleIdList></Reference><Reference><Citation>Mondola P, Damiano S, Sasso A, Santillo M. The Cu,Zn superoxide dismutase: not only a dismutase enzyme. Front Physiol 2016;7:594.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5126113</ArticleId><ArticleId IdType="pubmed">27965593</ArticleId></ArticleIdList></Reference><Reference><Citation>Ezzi SA, Urushitani M, Julien JP. Wild-type superoxide dismutase acquires binding and toxic properties of ALS-linked mutant forms through oxidation. J Neurochem. 2007;102:170&#x2013;178. doi: 10.1111/j.1471-4159.2007.04531.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1471-4159.2007.04531.x</ArticleId><ArticleId IdType="pubmed">17394546</ArticleId></ArticleIdList></Reference><Reference><Citation>Urushitani M, Sik A, Sakurai T, Nukina N, Takahashi R, Julien JP. Chromogranin-mediated secretion of mutant superoxide dismutase proteins linked to amyotrophic lateral sclerosis. Nat Neurosci. 2006;9:108&#x2013;118. doi: 10.1038/nn1603.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn1603</ArticleId><ArticleId IdType="pubmed">16369483</ArticleId></ArticleIdList></Reference><Reference><Citation>Jacobsson J, Jonsson PA, Andersen PM, Forsgren L, Marklund SL. Superoxide dismutase in CSF from amyotrophic lateral sclerosis patients with and without CuZn-superoxide dismutase mutations. Brain. 2001;124:1461&#x2013;1466. doi: 10.1093/brain/124.7.1461.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/124.7.1461</ArticleId><ArticleId IdType="pubmed">11408340</ArticleId></ArticleIdList></Reference><Reference><Citation>Winer L, Srinivasan D, Chun S, Lacomis D, Jaffa M, Fagan A, et al. SOD1 in cerebral spinal fluid as a pharmacodynamic marker for antisense oligonucleotide therapy. JAMA Neurol. 2013;70:201&#x2013;207. doi: 10.1001/jamaneurol.2013.593.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2013.593</ArticleId><ArticleId IdType="pmc">PMC3812918</ArticleId><ArticleId IdType="pubmed">23147550</ArticleId></ArticleIdList></Reference><Reference><Citation>Zetterstr&#xf6;m Per, Andersen Peter M., Br&#xe4;nnstr&#xf6;m Thomas, Marklund Stefan L. Misfolded superoxide dismutase-1 in CSF from amyotrophic lateral sclerosis patients. Journal of Neurochemistry. 2011;117(1):91&#x2013;99. doi: 10.1111/j.1471-4159.2011.07177.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1471-4159.2011.07177.x</ArticleId><ArticleId IdType="pubmed">21226712</ArticleId></ArticleIdList></Reference><Reference><Citation>Vijayalakshmi K, Alladi PA, Sathyaprabha TN, Subramaniam JR, Nalini A, Raju TR. Cerebrospinal fluid from sporadic amyotrophic lateral sclerosis patients induces degeneration of a cultured motor neuron cell line. Brain Res. 2009;1263:122&#x2013;133. doi: 10.1016/j.brainres.2009.01.041.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.brainres.2009.01.041</ArticleId><ArticleId IdType="pubmed">19368830</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu WC, Liang JZ, Li C, He ZX, Yuan HY, Huang BY, et al. Pathological hydrogen peroxide triggers the fibrillization of wild-type SOD1 via sulfenic acid modification of Cys-111. Cell Death Dis. 2018;9:67. doi: 10.1038/s41419-017-0106-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41419-017-0106-4</ArticleId><ArticleId IdType="pmc">PMC5833406</ArticleId><ArticleId IdType="pubmed">29358575</ArticleId></ArticleIdList></Reference><Reference><Citation>Wuolikainen A, Hedenstrom M, Moritz T, Marklund SL, Antti H, Andersen PM. Optimization of procedures for collecting and storing of CSF for studying the metabolome in ALS. Amyotroph Later Scler. 2009;10:229&#x2013;236. doi: 10.1080/17482960902871009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/17482960902871009</ArticleId><ArticleId IdType="pubmed">19412814</ArticleId></ArticleIdList></Reference><Reference><Citation>Majounie E, Renton AE, Mok K, Dopper EG, Waite A, Rollinson S, et al. Frequency of the C9orf72 hexanucleotide repeat expansion in patients with amyotrophic lateral sclerosis and frontotemporal dementia: a cross-sectional study. Lancet Neurol. 2012;11:323&#x2013;330. doi: 10.1016/S1474-4422(12)70043-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(12)70043-1</ArticleId><ArticleId IdType="pmc">PMC3322422</ArticleId><ArticleId IdType="pubmed">22406228</ArticleId></ArticleIdList></Reference><Reference><Citation>Cleary EM, Pal S, Azam T, Moore DJ, Swingler R, Gorrie G, et al. Improved PCR based methods for detecting C9orf72 hexanucleotide repeat expansions. Mol Cell Probes. 2016;30:218&#x2013;224. doi: 10.1016/j.mcp.2016.06.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mcp.2016.06.001</ArticleId><ArticleId IdType="pmc">PMC4978699</ArticleId><ArticleId IdType="pubmed">27288208</ArticleId></ArticleIdList></Reference><Reference><Citation>Ogaki Kotaro, Li Yuanzhe, Atsuta Naoki, Tomiyama Hiroyuki, Funayama Manabu, Watanabe Hazuki, Nakamura Ryoichi, Yoshino Hideo, Yato Seiji, Tamura Asako, Naito Yutaka, Taniguchi Akira, Fujita Koji, Izumi Yuishin, Kaji Ryuji, Hattori Nobutaka, Sobue Gen. Analysis of C9orf72 repeat expansion in 563 Japanese patients with amyotrophic lateral sclerosis. Neurobiology of Aging. 2012;33(10):2527.e11-2527.e16. doi: 10.1016/j.neurobiolaging.2012.05.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2012.05.011</ArticleId><ArticleId IdType="pubmed">22727276</ArticleId></ArticleIdList></Reference><Reference><Citation>Fujiwara Noriko, Nakano Miyako, Kato Shinsuke, Yoshihara Daisaku, Ookawara Tomomi, Eguchi Hironobu, Taniguchi Naoyuki, Suzuki Keiichiro. Oxidative Modification to Cysteine Sulfonic Acid of Cys111in Human Copper-Zinc Superoxide Dismutase. Journal of Biological Chemistry. 2007;282(49):35933&#x2013;35944. doi: 10.1074/jbc.M702941200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M702941200</ArticleId><ArticleId IdType="pubmed">17913710</ArticleId></ArticleIdList></Reference><Reference><Citation>Tokuda E, Anzai I, Nomura T, Toichi K, Watanabe M, Ohara S, et al. Immunochemical characterization on pathological oligomers of mutant Cu/Zn-superoxide dismutase in amyotrophic lateral sclerosis. Mol Neurodegener. 2017;12:2.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5216565</ArticleId><ArticleId IdType="pubmed">28057013</ArticleId></ArticleIdList></Reference><Reference><Citation>Tokuda Eiichi, Nomura Takao, Ohara Shinji, Watanabe Seiji, Yamanaka Koji, Morisaki Yuta, Misawa Hidemi, Furukawa Yoshiaki. A copper-deficient form of mutant Cu/Zn-superoxide dismutase as an early pathological species in amyotrophic lateral sclerosis. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease. 2018;1864(6):2119&#x2013;2130. doi: 10.1016/j.bbadis.2018.03.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbadis.2018.03.015</ArticleId><ArticleId IdType="pubmed">29551730</ArticleId></ArticleIdList></Reference><Reference><Citation>Furukawa Y, Torres AS, O'Halloran TV. Oxygen-induced maturation of SOD1: a key role for disulfide formation by the copper chaperone CCS. EMBO J. 2004;23:2872&#x2013;2881. doi: 10.1038/sj.emboj.7600276.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sj.emboj.7600276</ArticleId><ArticleId IdType="pmc">PMC1150991</ArticleId><ArticleId IdType="pubmed">15215895</ArticleId></ArticleIdList></Reference><Reference><Citation>Weydert CJ, Cullen JJ. Measurement of superoxide dismutase, catalase and glutathione peroxidase in cultured cells and tissue. Nat Protoc. 2010;5:51&#x2013;66. doi: 10.1038/nprot.2009.197.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nprot.2009.197</ArticleId><ArticleId IdType="pmc">PMC2830880</ArticleId><ArticleId IdType="pubmed">20057381</ArticleId></ArticleIdList></Reference><Reference><Citation>Wallberg Fredrik, Tenev Tencho, Meier Pascal. Analysis of Apoptosis and Necroptosis by Fluorescence-Activated Cell Sorting. Cold Spring Harbor Protocols. 2016;2016(4):pdb.prot087387. doi: 10.1101/pdb.prot087387.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/pdb.prot087387</ArticleId><ArticleId IdType="pubmed">27037070</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakamura A, Hineno A, Yoshida K, Sekijima Y, Hanaoka-Tachibana N, Takei Y, et al. Marked intrafamilial phenotypic variation in a family with SOD1 C111Y mutation. Amyotroph Later Scler. 2012;13:479&#x2013;486. doi: 10.3109/17482968.2012.656311.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/17482968.2012.656311</ArticleId><ArticleId IdType="pubmed">22409359</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilcox KC, Zhou L, Jordon JK, Huang Y, Yu Y, Redler RL, et al. Modifications of superoxide dismutase (SOD1) in human erythrocytes: a possible role in amyotrophic lateral sclerosis. J Biol Chem. 2009;284:13940&#x2013;13947. doi: 10.1074/jbc.M809687200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M809687200</ArticleId><ArticleId IdType="pmc">PMC2679493</ArticleId><ArticleId IdType="pubmed">19299510</ArticleId></ArticleIdList></Reference><Reference><Citation>Urushitani M, Ezzi SA, Julien JP. Therapeutic effects of immunization with mutant superoxide dismutase in mice models of amyotrophic lateral sclerosis. Proc Natl Acad Sci U S A. 2007;104:2495&#x2013;2500. doi: 10.1073/pnas.0606201104.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0606201104</ArticleId><ArticleId IdType="pmc">PMC1790867</ArticleId><ArticleId IdType="pubmed">17277077</ArticleId></ArticleIdList></Reference><Reference><Citation>Rakhit R, Robertson J, Vande Velde C, Horne P, Ruth DM, Griffin J, et al. An immunological epitope selective for pathological monomer-misfolded SOD1 in ALS. Nat Med. 2007;13:754&#x2013;759. doi: 10.1038/nm1559.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm1559</ArticleId><ArticleId IdType="pubmed">17486090</ArticleId></ArticleIdList></Reference><Reference><Citation>Rotunno MS, Auclair JR, Maniatis S, Shaffer SA, Agar J, Bosco DA. Identification of a misfolded region in superoxide dismutase 1 that is exposed in amyotrophic lateral sclerosis. J Biol Chem. 2014;289:28527&#x2013;28538. doi: 10.1074/jbc.M114.581801.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M114.581801</ArticleId><ArticleId IdType="pmc">PMC4192504</ArticleId><ArticleId IdType="pubmed">25164820</ArticleId></ArticleIdList></Reference><Reference><Citation>Forman HJ, Fridovich I. On the stability of bovine superoxide dismutase. The effects of metals. J Biol Chem. 1973;248:2645&#x2013;2649.</Citation><ArticleIdList><ArticleId IdType="pubmed">4697386</ArticleId></ArticleIdList></Reference><Reference><Citation>Furukawa Y, O&#x2019;Halloran TV. Amyotrophic lateral sclerosis mutations have the greatest destabilizing effect on the apo, reduced form of SOD1, leading to unfolding and oxidative aggregation. J Biol Chem. 2005;280:17266&#x2013;17274. doi: 10.1074/jbc.M500482200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M500482200</ArticleId><ArticleId IdType="pubmed">15691826</ArticleId></ArticleIdList></Reference><Reference><Citation>Stathopulos PB, Rumfeldt JA, Scholz GA, Irani RA, Frey HE, Hallewell RA, et al. Cu/Zn superoxide dismutase mutants associated with amyotrophic lateral sclerosis show enhanced formation of aggregates in vitro. Proc Natl Acad Sci U S A. 2003;100:7021&#x2013;7026. doi: 10.1073/pnas.1237797100.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1237797100</ArticleId><ArticleId IdType="pmc">PMC165823</ArticleId><ArticleId IdType="pubmed">12773627</ArticleId></ArticleIdList></Reference><Reference><Citation>Crow JP, Sampson JB, Zhuang Y, Thompson JA, Beckman JS. Decreased zinc affinity of amyotrophic lateral sclerosis-associated superoxide dismutase mutants leads to enhanced catalysis of tyrosine nitration by peroxynitrite. J Neurochem. 1997;69:1936&#x2013;1944. doi: 10.1046/j.1471-4159.1997.69051936.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1471-4159.1997.69051936.x</ArticleId><ArticleId IdType="pubmed">9349538</ArticleId></ArticleIdList></Reference><Reference><Citation>Hozumi I, Hasegawa T, Honda A, Ozawa K, Hayashi Y, Hashimoto K, et al. Patterns of levels of biological metals in CSF differ among neurodegenerative diseases. J Neurol Sci. 2011;303:95&#x2013;99. doi: 10.1016/j.jns.2011.01.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jns.2011.01.003</ArticleId><ArticleId IdType="pubmed">21292280</ArticleId></ArticleIdList></Reference><Reference><Citation>Ihara Y, Nobukuni K, Takata H, Hayabara T. Oxidative stress and metal content in blood and cerebrospinal fluid of amyotrophic lateral sclerosis patients with and without a cu, Zn-superoxide dismutase mutation. Neurol Res. 2005;27:105&#x2013;108. doi: 10.1179/016164105X18430.</Citation><ArticleIdList><ArticleId IdType="doi">10.1179/016164105X18430</ArticleId><ArticleId IdType="pubmed">15829169</ArticleId></ArticleIdList></Reference><Reference><Citation>Roos PM, Vesterberg O, Syversen T, Flaten TP, Nordberg M. Metal concentrations in cerebrospinal fluid and blood plasma from patients with amyotrophic lateral sclerosis. Biol Trace Elem Res. 2013;151:159&#x2013;170. doi: 10.1007/s12011-012-9547-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12011-012-9547-x</ArticleId><ArticleId IdType="pubmed">23225075</ArticleId></ArticleIdList></Reference><Reference><Citation>Boll MC, Alcaraz-Zubeldia M, Montes S, Rios C. Free copper, ferroxidase and SOD1 activities, lipid peroxidation and NO(x) content in the CSF. A different marker profile in four neurodegenerative diseases. Neurochem Res. 2008;33:1717&#x2013;1723. doi: 10.1007/s11064-008-9610-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11064-008-9610-3</ArticleId><ArticleId IdType="pubmed">18307039</ArticleId></ArticleIdList></Reference><Reference><Citation>Olivieri S, Conti A, Iannaccone S, Cannistraci CV, Campanella A, Barbariga M, et al. Ceruloplasmin oxidation, a feature of Parkinson's disease CSF, inhibits ferroxidase activity and promotes cellular iron retention. J Neurosci. 2011;31:18568&#x2013;18577. doi: 10.1523/JNEUROSCI.3768-11.2011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.3768-11.2011</ArticleId><ArticleId IdType="pmc">PMC6623910</ArticleId><ArticleId IdType="pubmed">22171055</ArticleId></ArticleIdList></Reference><Reference><Citation>Opacic M, Stevic Z, Bascarevic V, Zivic M, Spasic M, Spasojevic I. Can oxidation-reduction potential of cerebrospinal fluid be a monitoring biomarker in amyotrophic lateral sclerosis? Antioxid Redox Signal. 2018;28:1570&#x2013;1575. doi: 10.1089/ars.2017.7433.</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/ars.2017.7433</ArticleId><ArticleId IdType="pubmed">29113448</ArticleId></ArticleIdList></Reference><Reference><Citation>Mulligan VK, Kerman A, Laister RC, Sharda PR, Arslan PE, Chakrabartty A. Early steps in oxidation-induced SOD1 misfolding: implications for non-amyloid protein aggregation in familial ALS. J Mol Biol. 2012;421:631&#x2013;652. doi: 10.1016/j.jmb.2012.04.016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jmb.2012.04.016</ArticleId><ArticleId IdType="pubmed">22542526</ArticleId></ArticleIdList></Reference><Reference><Citation>Rakhit R, Cunningham P, Furtos-Matei A, Dahan S, Qi XF, Crow JP, et al. Oxidation-induced misfolding and aggregation of superoxide dismutase and its implications for amyotrophic lateral sclerosis. J Biol Chem. 2002;277:47551&#x2013;47556. doi: 10.1074/jbc.M207356200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M207356200</ArticleId><ArticleId IdType="pubmed">12356748</ArticleId></ArticleIdList></Reference><Reference><Citation>Hornburg D, Drepper C, Butter F, Meissner F, Sendtner M, Mann M. Deep proteomic evaluation of primary and cell line motoneuron disease models delineates major differences in neuronal characteristics. Mol Cell Proteomics. 2014;13:3410&#x2013;3420. doi: 10.1074/mcp.M113.037291.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/mcp.M113.037291</ArticleId><ArticleId IdType="pmc">PMC4256493</ArticleId><ArticleId IdType="pubmed">25193168</ArticleId></ArticleIdList></Reference><Reference><Citation>Bruijn LI, Houseweart MK, Kato S, Anderson KL, Anderson SD, Ohama E, et al. Aggregation and motor neuron toxicity of an ALS-linked SOD1 mutant independent from wild-type SOD1. Science. 1998;281:1851&#x2013;1854. doi: 10.1126/science.281.5384.1851.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.281.5384.1851</ArticleId><ArticleId IdType="pubmed">9743498</ArticleId></ArticleIdList></Reference><Reference><Citation>Doherty MJ, Bird TD, Leverenz JB. Alpha-synuclein in motor neuron disease: an immunohistologic study. Acta Neuropathol. 2004;107:169&#x2013;175. doi: 10.1007/s00401-003-0790-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-003-0790-2</ArticleId><ArticleId IdType="pubmed">14648076</ArticleId></ArticleIdList></Reference><Reference><Citation>Mezey E, Dehejia A, Harta G, Papp MI, Polymeropoulos MH, Brownstein MJ. Alpha synuclein in neurodegenerative disorders: murderer or accomplice? Nat Med. 1998;4:755&#x2013;757. doi: 10.1038/nm0798-755.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm0798-755</ArticleId><ArticleId IdType="pubmed">9662355</ArticleId></ArticleIdList></Reference><Reference><Citation>Qureshi AI, Wilmot G, Dihenia B, Schneider JA, Krendel DA. Motor neuron disease with parkinsonism. Arch Neurol. 1996;53:987&#x2013;991. doi: 10.1001/archneur.1996.00550100061015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archneur.1996.00550100061015</ArticleId><ArticleId IdType="pubmed">8859060</ArticleId></ArticleIdList></Reference><Reference><Citation>Brinker T, Stopa E, Morrison J, Klinge P. A new look at cerebrospinal fluid circulation. Fluids Barriers CNS. 2014;11:10. doi: 10.1186/2045-8118-11-10.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/2045-8118-11-10</ArticleId><ArticleId IdType="pmc">PMC4016637</ArticleId><ArticleId IdType="pubmed">24817998</ArticleId></ArticleIdList></Reference><Reference><Citation>Barber SC, Shaw PJ. Oxidative stress in ALS: key role in motor neuron injury and therapeutic target. Free Radic Biol Med. 2010;48:629&#x2013;641. doi: 10.1016/j.freeradbiomed.2009.11.018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.freeradbiomed.2009.11.018</ArticleId><ArticleId IdType="pubmed">19969067</ArticleId></ArticleIdList></Reference><Reference><Citation>Furukawa Y. Protein aggregates in pathological inclusions of amyotrophic lateral sclerosis. In: Amyotrophic lateral sclerosis (Maurer, M.H. ed.) InTech, Rijeka, Croatia; 2012. p. 335&#x2013;56.</Citation></Reference><Reference><Citation>Mondola P, Ruggiero G, Seru R, Damiano S, Grimaldi S, Garbi C, et al. The Cu,Zn superoxide dismutase in neuroblastoma SK-N-BE cells is exported by a microvesicles dependent pathway. Brain Res Mol Brain Res. 2003;110:45&#x2013;51. doi: 10.1016/S0169-328X(02)00583-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0169-328X(02)00583-1</ArticleId><ArticleId IdType="pubmed">12573532</ArticleId></ArticleIdList></Reference><Reference><Citation>Gomes C, Keller S, Altevogt P, Costa J. Evidence for secretion of Cu,Zn superoxide dismutase via exosomes from a cell model of amyotrophic lateral sclerosis. Neurosci Lett. 2007;428:43&#x2013;46. doi: 10.1016/j.neulet.2007.09.024.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neulet.2007.09.024</ArticleId><ArticleId IdType="pubmed">17942226</ArticleId></ArticleIdList></Reference><Reference><Citation>Silverman JM, Christy D, Shyu CC, Moon KM, Fernando S, Gidden Z, et al. CNS-derived extracellular vesicles from superoxide dismutase 1 (SOD1)(G93A) ALS mice originate from astrocytes and neurons and carry misfolded SOD1. J Biol Chem. 2019;294:3744&#x2013;3759. doi: 10.1074/jbc.RA118.004825.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.RA118.004825</ArticleId><ArticleId IdType="pmc">PMC6416428</ArticleId><ArticleId IdType="pubmed">30635404</ArticleId></ArticleIdList></Reference><Reference><Citation>Bergh Johan, Zetterstr&#xf6;m Per, Andersen Peter M., Br&#xe4;nnstr&#xf6;m Thomas, Graffmo Karin S., Jonsson P. Andreas, Lang Lisa, Danielsson Jens, Oliveberg Mikael, Marklund Stefan L. Structural and kinetic analysis of protein-aggregate strains in vivo using binary epitope mapping. Proceedings of the National Academy of Sciences. 2015;112(14):4489&#x2013;4494. doi: 10.1073/pnas.1419228112.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1419228112</ArticleId><ArticleId IdType="pmc">PMC4394267</ArticleId><ArticleId IdType="pubmed">25802384</ArticleId></ArticleIdList></Reference><Reference><Citation>Ekhtiari Bidhendi Elaheh, Bergh Johan, Zetterstr&#xf6;m Per, Forsberg Karin, Pakkenberg Bente, Andersen Peter M., Marklund Stefan L., Br&#xe4;nnstr&#xf6;m Thomas. Mutant superoxide dismutase aggregates from human spinal cord transmit amyotrophic lateral sclerosis. Acta Neuropathologica. 2018;136(6):939&#x2013;953. doi: 10.1007/s00401-018-1915-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-018-1915-y</ArticleId><ArticleId IdType="pmc">PMC6280858</ArticleId><ArticleId IdType="pubmed">30284034</ArticleId></ArticleIdList></Reference><Reference><Citation>Grad LI, Guest WC, Yanai A, Pokrishevsky E, O'Neill MA, Gibbs E, et al. Intermolecular transmission of superoxide dismutase 1 misfolding in living cells. Proc Natl Acad Sci U S A. 2011;108:16398&#x2013;16403. doi: 10.1073/pnas.1102645108.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1102645108</ArticleId><ArticleId IdType="pmc">PMC3182705</ArticleId><ArticleId IdType="pubmed">21930926</ArticleId></ArticleIdList></Reference><Reference><Citation>Ravits JM, La Spada AR. ALS motor phenotype heterogeneity, focality, and spread: deconstructing motor neuron degeneration. Neurology. 2009;73:805&#x2013;811. doi: 10.1212/WNL.0b013e3181b6bbbd.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0b013e3181b6bbbd</ArticleId><ArticleId IdType="pmc">PMC2739608</ArticleId><ArticleId IdType="pubmed">19738176</ArticleId></ArticleIdList></Reference><Reference><Citation>Kanouchi T, Ohkubo T, Yokota T. Can regional spreading of amyotrophic lateral sclerosis motor symptoms be explained by prion-like propagation? J Neurol Neurosurg Psychiatry. 2012;83:739&#x2013;745. doi: 10.1136/jnnp-2011-301826.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2011-301826</ArticleId><ArticleId IdType="pmc">PMC3368493</ArticleId><ArticleId IdType="pubmed">22544947</ArticleId></ArticleIdList></Reference><Reference><Citation>Walhout R, Verstraete E, van den Heuvel MP, Veldink JH, van den Berg LH. Patterns of symptom development in patients with motor neuron disease. Amyotroph Later Scler Frontotempor Degener. 2018;19:21&#x2013;28. doi: 10.1080/21678421.2017.1386688.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2017.1386688</ArticleId><ArticleId IdType="pubmed">29037065</ArticleId></ArticleIdList></Reference><Reference><Citation>van Blitterswijk M, Gulati S, Smoot E, Jaffa M, Maher N, Hyman BT, et al. Anti-superoxide dismutase antibodies are associated with survival in patients with sporadic amyotrophic lateral sclerosis. Amyotroph Later Scler. 2011;12:430&#x2013;438. doi: 10.3109/17482968.2011.585163.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/17482968.2011.585163</ArticleId><ArticleId IdType="pmc">PMC3446817</ArticleId><ArticleId IdType="pubmed">22023190</ArticleId></ArticleIdList></Reference><Reference><Citation>Maier Marcel, Welt Tobias, Wirth Fabian, Montrasio Fabio, Preisig Daniel, McAfoose Jordan, Vieira Fernando G., Kulic Luka, Sp&#xe4;ni Claudia, Stehle Thilo, Perrin Steve, Weber Markus, Hock Christoph, Nitsch Roger M., Grimm Jan. A human-derived antibody targets misfolded SOD1 and ameliorates motor symptoms in mouse models of amyotrophic lateral sclerosis. Science Translational Medicine. 2018;10(470):eaah3924. doi: 10.1126/scitranslmed.aah3924.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.aah3924</ArticleId><ArticleId IdType="pubmed">30518612</ArticleId></ArticleIdList></Reference><Reference><Citation>Finsterer J, Mamoli B. Cerebrospinal fluid filtration in amyotrophic lateral sclerosis. Eur J Neurol. 1999;6:597&#x2013;600. doi: 10.1046/j.1468-1331.1999.650597.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1468-1331.1999.650597.x</ArticleId><ArticleId IdType="pubmed">10457394</ArticleId></ArticleIdList></Reference><Reference><Citation>Finsterer J, Mamoli B. Liquorpheresis (CSF filtration) in familial amyotrophic lateral sclerosis. Spinal Cord. 1999;37:592&#x2013;593. doi: 10.1038/sj.sc.3100857.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sj.sc.3100857</ArticleId><ArticleId IdType="pubmed">10455537</ArticleId></ArticleIdList></Reference><Reference><Citation>Menendez GM. Implantable systems for continuous liquorpheresis and CSF replacement. Cureus. 2017;9:e1022.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5388363</ArticleId><ArticleId IdType="pubmed">28413734</ArticleId></ArticleIdList></Reference><Reference><Citation>Wollinsky KH, Hulser PJ, Brinkmeier H, Aulkemeyer P, Bossenecker W, Huber-Hartmann KH, et al. CSF filtration is an effective treatment of Guillain-Barre syndrome: a randomized clinical trial. Neurology. 2001;57:774&#x2013;780. doi: 10.1212/WNL.57.5.774.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.57.5.774</ArticleId><ArticleId IdType="pubmed">11552002</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>